CA
NZ
UK
AU
IND
US
HHS's decision to establish two new deputy commissioner roles at the FDA marks a key shift in the agency's approach to innovation in healthcare. The primary focus will be on technology applications and drug development, which are essential as the industry evolves. This move …
Theravance Biopharma, Inc. (NASDAQ: TBPH) released findings from the Phase 3 CYPRESS study of ampreloxetine, revealing that the primary endpoint change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score at week 8 was not statistically significant. This result suggests challenges in the overall …
Miles Suk has resigned as Chief Executive Officer of Abpro Holdings, Inc. a move effective August 19, 2026. This resignation is notable as it occurred without any reported disagreements concerning the company's operations or policies. Following his departure, theBoard of Directorshas appointed M. Fatih …
Tonix Pharmaceuticals (NASDAQ:TNXP) climbed 9.72% in a session that put the long-suffering specialty-pharma name back on the most-active lists, extending a stretch of renewed attention around its newly launched fibromyalgia therapy.
TherapeuticsMD, Inc. (NASDAQ:TXMD), a women's-health company reinvented as a lean licensing and royalty business, climbed 10.14% in a session that spotlighted one of the market's quieter micro-cap comebacks. The move reflected renewed interest in a name that has transformed itself almost beyond recognition.
Treace Medical Concepts (NASDAQ:TMCI), the company behind the Lapiplasty bunion-correction system, surged 10.07% as investors bet on a cautious rebound following a challenging stretch for the foot-and-ankle specialist. The move suggested the market is beginning to look past a period of decelerating growth.
● TNON shares fell 10.94% following a turbulent stretch that included a 1-for-35Reverse Stock Splitexecuted to maintain Nasdaq's minimum-bid compliance.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biotech developing treatments for cystic fibrosis, rose 11.81% in a session that read as a partial rebound after a punishing stretch. The move followed a closely watched data release that delivered both a clear disappointment and a glimmer of …
● SCTX shares fell 16.23%, pulling back from the low $30s after more than doubling from its $15 IPO price in late July.
REGENXBIO (NASDAQ:RGNX) climbed 10.61% to about $8.91, a notable rebound for a gene-therapy developer that has weathered a turbulent stretch. The company sits at a pivotal moment, preparing a key regulatory submission for its Duchenne muscular dystrophy program even as it manages the fallout …
Please wait processing your request...